Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff with manufacturers over access to 340B pricing in the contract pharmacy setting.
“It is clear manufacturers are focused on protecting profit margins at the expense of the most vulnerable and underserved patients,” the National Association of Community Health Centers (NACHC) told 340B Report in the wake of a U.S. Department of Health and Human Services’ ADR panel dismissal which 340B Report obtained this week. “Health centers cannot wait any longer for a solution, NACHC said. “Health centers need Congress to move urgently to protect and strengthen the 340B program before it’s too late.”
Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff with manufacturers over access to 340B pricing in the contract pharmacy setting.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
